150 related articles for article (PubMed ID: 10779436)
1. Defensins are dominant HLA-DR-associated self-peptides from CD34(-) peripheral blood mononuclear cells of different tumor patients (plasmacytoma, chronic myeloid leukemia).
Halder TM; Blüggel M; Heinzel S; Pawelec G; Meyer HE; Kalbacher H
Blood; 2000 May; 95(9):2890-6. PubMed ID: 10779436
[TBL] [Abstract][Full Text] [Related]
2. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors.
Pawelec G; Max H; Halder T; Bruserud O; Merl A; da Silva P; Kalbacher H
Blood; 1996 Sep; 88(6):2118-24. PubMed ID: 8822931
[TBL] [Abstract][Full Text] [Related]
3. Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils.
Chertov O; Michiel DF; Xu L; Wang JM; Tani K; Murphy WJ; Longo DL; Taub DD; Oppenheim JJ
J Biol Chem; 1996 Feb; 271(6):2935-40. PubMed ID: 8621683
[TBL] [Abstract][Full Text] [Related]
4. Predominant HLA-class II bound self-peptides of a hematopoietic progenitor cell line are derived from intracellular proteins.
Harris PE; Maffei A; Colovai AI; Kinne J; Tugulea S; Suciu-Foca N
Blood; 1996 Jun; 87(12):5104-12. PubMed ID: 8652823
[TBL] [Abstract][Full Text] [Related]
5. CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.
Yasukawa M; Ohminami H; Kaneko S; Yakushijin Y; Nishimura Y; Inokuchi K; Miyakuni T; Nakao S; Kishi K; Kubonishi I; Dan K; Fujita S
Blood; 1998 Nov; 92(9):3355-61. PubMed ID: 9787173
[TBL] [Abstract][Full Text] [Related]
6. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes.
Yasukawa M; Ohminami H; Kojima K; Hato T; Hasegawa A; Takahashi T; Hirai H; Fujita S
Blood; 2001 Sep; 98(5):1498-505. PubMed ID: 11520800
[TBL] [Abstract][Full Text] [Related]
7. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide.
Bosch GJ; Joosten AM; Kessler JH; Melief CJ; Leeksma OC
Blood; 1996 Nov; 88(9):3522-7. PubMed ID: 8896419
[TBL] [Abstract][Full Text] [Related]
8. Idarubicin, intermediate-dose cytarabine, etoposide, and granulocyte-colony-stimulating factor are able to recruit CD34+/HLA-DR- cells during early hematopoietic recovery in accelerated and chronic phases of chronic myeloid leukemia.
Carella AM; Frassoni F; Podestá M; Pungolino E; Pollicardo N; Ferrero R; Soracco M
J Hematother; 1994; 3(3):199-202. PubMed ID: 7530135
[TBL] [Abstract][Full Text] [Related]
9. The alpha-defensins HNP-1 and HNP-2 are dominant self-peptides presented by HLA class-II molecules in lesional psoriatic skin.
Boehncke WH
Eur J Dermatol; 2004; 14(3):142-5. PubMed ID: 15246937
[TBL] [Abstract][Full Text] [Related]
10. Role of CCAAT/enhancer-binding protein site in transcription of human neutrophil peptide-1 and -3 defensin genes.
Tsutsumi-Ishii Y; Hasebe T; Nagaoka I
J Immunol; 2000 Mar; 164(6):3264-73. PubMed ID: 10706719
[TBL] [Abstract][Full Text] [Related]
11. Human monoclonal antibody with T-cell-like specificity recognizes MHC class I self-peptide presented by HLA-DR1 on activated cells.
Wölpl A; Halder T; Kalbacher H; Neumeyer H; Siemoneit K; Goldmann SF; Eiermann TH
Tissue Antigens; 1998 Mar; 51(3):258-69. PubMed ID: 9550326
[TBL] [Abstract][Full Text] [Related]
12. Synthetic peptides derived from the Wilms' tumor 1 protein sensitize human T lymphocytes to recognize chronic myelogenous leukemia cells.
Müller L; Knights A; Pawelec G
Hematol J; 2003; 4(1):57-66. PubMed ID: 12692522
[TBL] [Abstract][Full Text] [Related]
13. Purification and characterization of human neutrophil peptide 4, a novel member of the defensin family.
Wilde CG; Griffith JE; Marra MN; Snable JL; Scott RW
J Biol Chem; 1989 Jul; 264(19):11200-3. PubMed ID: 2500436
[TBL] [Abstract][Full Text] [Related]
14. T cell alloreactivity induced by normal G-CSF-mobilized CD34+ blood cells.
Rondelli D; Anasetti C; Fortuna A; Ratta M; Arpinati M; Bandini G; Lemoli RM; Tura S
Bone Marrow Transplant; 1998 Jun; 21(12):1183-91. PubMed ID: 9674849
[TBL] [Abstract][Full Text] [Related]
15. HLA-DR1 (DRB1*0101) and DR4 (DRB1*0401) use the same anchor residues for binding an immunodominant peptide derived from human type II collagen.
Rosloniec EF; Whittington KB; Zaller DM; Kang AH
J Immunol; 2002 Jan; 168(1):253-9. PubMed ID: 11751969
[TBL] [Abstract][Full Text] [Related]
16. Recognition of HLA-DR1/DRB1*0101 molecules presenting HLA-A2 derived peptides by a human recombinant antibody, Fab-5 A1.
Löffler D; Welschof M; Goldmann SF; Wölpl A
Eur J Immunogenet; 1998 Oct; 25(5):339-47. PubMed ID: 9805656
[TBL] [Abstract][Full Text] [Related]
17. HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates.
Mannering SI; McKenzie JL; Fearnley DB; Hart DN
Blood; 1997 Jul; 90(1):290-7. PubMed ID: 9207464
[TBL] [Abstract][Full Text] [Related]
18. Identification of HLA-DR1 beta chain residues critical for binding staphylococcal enterotoxins A and E.
Karp DR; Long EO
J Exp Med; 1992 Feb; 175(2):415-24. PubMed ID: 1370684
[TBL] [Abstract][Full Text] [Related]
19. Transplantation of allogeneic CD34+ blood cells.
Link H; Arseniev L; Bähre O; Kadar JG; Diedrich H; Poliwoda H
Blood; 1996 Jun; 87(11):4903-9. PubMed ID: 8639865
[TBL] [Abstract][Full Text] [Related]
20. BCR/ABL- CD34(+)HLA-DR- progenitor cells in early chronic phase, but not in more advanced phases, of chronic myelogenous leukemia are polyclonal.
Delforge M; Boogaerts MA; McGlave PB; Verfaillie CM
Blood; 1999 Jan; 93(1):284-92. PubMed ID: 9864172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
